Physician

Mark Kim Walsh, M.D.,PHD

According to 2025 Medicare claims, Mark Walsh, M.D., PHD (NPI: 1003952318) practices ophthalmology in the Tucson, AZ market, with the plurality of this provider's patient population coming from Pima, AZ. This provider's primary affiliated billing organization is RASW, PC (NPI: 1407916992; TIN: 86-0891570) and primary practice location at 85712-2845.

Walsh's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,426 traditional Medicare patients, billed 87,495 HCPCS/CPT codes, and received $4,934,739 in Medicare payments. The top billing code was 67028 (Injection of drug into eye). Part D data shows 811 prescription claims across 263 beneficiaries totaling $92,196 in drug costs, led by Prednisolone Acetate (Prednisolone Acetate). Open Payments data shows 11 records totaling $956. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $2,492,534 to $4,934,739. Similarly, Part D prescription costs have risen steadily, from $23,737 to $92,196. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,258	19,555	$2,492,534
2016	1,301	18,940	$2,507,560
2017	1,437	19,660	$2,408,337
2018	1,514	22,077	$2,871,150
2019	1,472	20,399	$2,790,817
2020	1,410	18,088	$2,795,521
2021	1,272	19,105	$3,221,570
2022	1,210	22,746	$3,871,394
2023	1,224	57,898	$4,213,855
2024	1,426	87,495	$4,934,739

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	132	449	$23,737
2016	141	432	$21,905
2017	156	482	$24,480
2018	173	541	$35,826
2019	201	545	$42,129
2020	201	589	$45,380
2021	223	626	$42,970
2022	185	494	$32,944
2023	211	592	$38,422
2024	263	811	$92,196

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
67028	Injection of drug into eye	534	2,236	$108
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	567	2,224	$105
92014	Established patient complete exam of visual system	757	1,081	$92
92134	Imaging of retina	1,403	3,757	$32
92202	Extended exam of the back part of the eye with optic nerve drawing	699	1,004	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Prednisolone Acetate	Prednisolone Acetate	308	12,975	$15,858
Difluprednate	Difluprednate	37	1,841	$4,590
Ketorolac Tromethamine	Ketorolac Tromethamine	120	5,454	$3,081
Bromfenac Sodium	Bromfenac Sodium	15	454	$2,673
Neomycin-Polymyxin-Dexameth	Neomycin/Polymyxin B/Dexametha	158	3,708	$1,984

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	11	$956	Alimera Sciences, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mark Kim Walsh, M.D., PHD?

Tedicare shows public-source Medicare data for Mark Kim Walsh, M.D., PHD (NPI 1003952318), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mark Kim Walsh, M.D., PHD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Mark Kim Walsh, M.D., PHD?

Mark Kim Walsh, M.D., PHD is linked to RASW, PC (billing NPI 1407916992) in the available physician profile data.

Does Mark Kim Walsh, M.D., PHD have Open Payments data?

Mark Kim Walsh, M.D., PHD has 11 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.